RecruitingNCT04230785

Circulating Non-coding RNA in Acute Ischemic Stroke with Endovascular Treatment (EVTRNA)

Clinical Significance of Circulating Non-coding RNA in Acute Ischemic Stroke with Endovascular Treatment (EVTRNA)


Sponsor

Nanjing First Hospital, Nanjing Medical University

Enrollment

300 participants

Start Date

Mar 15, 2020

Study Type

OBSERVATIONAL

Conditions

Summary

EVTRNA is to analyze the differentiated expression pattern of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA) by next-generation sequencing in acute ischemic stroke patients before and/or after endovascular treatment. The candidate circRNA/lncRNA/miRNA will be verified as the biomarker and regulator for progression and prognosis of acute ischemic stroke with endovascular treatment. Further, the candidate non-coding RNA will be used to evaluate the effect of endovascular treatment on both peripheral and central immune after stroke.


Eligibility

Min Age: 18 YearsMax Age: 90 Years

Inclusion Criteria5

  • Aged 18 years or older
  • Confirmed acute ischemic stroke by a diffusion-weighted imaging-position lesion on magnetic resonance imaging (MRI) and a new lesion on a brain computed tomography (CT) scan
  • Within 24 hours of symptom onset and treat with endovascular therapy
  • Good performance status
  • Signed an approved informed consents

Exclusion Criteria1

  • a history of hemorrhagic infarction, chronic kidney/liver diseases, peripheral arterial occlusive disease, active malignant disease, and inflammatory or infectious diseases

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

GENETICSequencing of circRNA/lncRNA/miRNA

Next generation sequencing and quantitative real-time polymerase chain reaction of circular RNA (circRNA), long non-coding RNA (lncRNA) and micro-RNA (miRNA)


Locations(1)

Nanjing First Hospital, Nanjing Medical University

Nanjing, Jiangsu, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04230785


Related Trials